SE453504B - N-metyl-d-glukaminsalt av 3,4-dihydro-5-metyl-6-(2-metylpropyl)-4-oxotieno(2,3-d)-pyrimidin-2-karboxylsyra och farmaceutisk komposition innehallande detta salt - Google Patents
N-metyl-d-glukaminsalt av 3,4-dihydro-5-metyl-6-(2-metylpropyl)-4-oxotieno(2,3-d)-pyrimidin-2-karboxylsyra och farmaceutisk komposition innehallande detta saltInfo
- Publication number
- SE453504B SE453504B SE8204792A SE8204792A SE453504B SE 453504 B SE453504 B SE 453504B SE 8204792 A SE8204792 A SE 8204792A SE 8204792 A SE8204792 A SE 8204792A SE 453504 B SE453504 B SE 453504B
- Authority
- SE
- Sweden
- Prior art keywords
- methyl
- salt
- glucamine
- methylpropyl
- dihydro
- Prior art date
Links
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 title claims description 10
- KTOQRRDVVIDEAA-UHFFFAOYSA-N 2-methylpropane Chemical class [CH2]C(C)C KTOQRRDVVIDEAA-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims description 30
- 239000000243 solution Substances 0.000 claims description 19
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- WIZAMTSKPRSWIL-UHFFFAOYSA-N tiprinast Chemical compound N1=C(C(O)=O)NC(=O)C2=C1SC(CC(C)C)=C2C WIZAMTSKPRSWIL-UHFFFAOYSA-N 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 206010045240 Type I hypersensitivity Diseases 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 231100000344 non-irritating Toxicity 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- ZFCHNZDUMIOWFV-UHFFFAOYSA-N pyrimidine-2-carboxylic acid Chemical compound OC(=O)C1=NC=CC=N1 ZFCHNZDUMIOWFV-UHFFFAOYSA-N 0.000 claims 1
- 239000000376 reactant Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- -1 amine salt Chemical class 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- OPEPFDHEYUYTMO-WZTVWXICSA-N (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol;5-methyl-6-(2-methylpropyl)-4-oxo-3h-thieno[2,3-d]pyrimidine-2-carboxylic acid Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.N1=C(C(O)=O)NC(=O)C2=C1SC(CC(C)C)=C2C OPEPFDHEYUYTMO-WZTVWXICSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- CDMIETFBAJYVHS-UHFFFAOYSA-L O.CC1=C(SC=2N=C(NC(C21)=O)C(=O)[O-])CC(C)C.[K+].[K+].CC2=C(SC=1N=C(NC(C12)=O)C(=O)[O-])CC(C)C Chemical compound O.CC1=C(SC=2N=C(NC(C21)=O)C(=O)[O-])CC(C)C.[K+].[K+].CC2=C(SC=1N=C(NC(C12)=O)C(=O)[O-])CC(C)C CDMIETFBAJYVHS-UHFFFAOYSA-L 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 150000001721 carbon Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical class [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/294,962 US4377583A (en) | 1981-08-21 | 1981-08-21 | N-Methyl-D-glucamine salt of with 3,4-dihydro-5-methyl-6-(2-methylpropyl)-4-oxothieno[2,3-d]pyrimidine-2-carboxylic acid |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE8204792D0 SE8204792D0 (sv) | 1982-08-20 |
| SE8204792L SE8204792L (sv) | 1983-02-22 |
| SE453504B true SE453504B (sv) | 1988-02-08 |
Family
ID=23135663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8204792A SE453504B (sv) | 1981-08-21 | 1982-08-20 | N-metyl-d-glukaminsalt av 3,4-dihydro-5-metyl-6-(2-metylpropyl)-4-oxotieno(2,3-d)-pyrimidin-2-karboxylsyra och farmaceutisk komposition innehallande detta salt |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US4377583A (lv) |
| JP (1) | JPS5843976A (lv) |
| KR (1) | KR870001240B1 (lv) |
| AT (1) | AT381314B (lv) |
| AU (1) | AU558004B2 (lv) |
| BE (1) | BE894162A (lv) |
| CA (1) | CA1224465A (lv) |
| CH (1) | CH651569A5 (lv) |
| DE (1) | DE3231103A1 (lv) |
| DK (1) | DK164059C (lv) |
| ES (1) | ES8401074A1 (lv) |
| FI (1) | FI74965C (lv) |
| FR (1) | FR2511680B1 (lv) |
| GB (1) | GB2104521B (lv) |
| GR (1) | GR76250B (lv) |
| IE (1) | IE53804B1 (lv) |
| IT (1) | IT1149064B (lv) |
| LU (1) | LU84346A1 (lv) |
| MY (1) | MY8800122A (lv) |
| NL (1) | NL8203280A (lv) |
| PT (1) | PT75446A (lv) |
| SE (1) | SE453504B (lv) |
| ZA (1) | ZA826019B (lv) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5753701A (en) * | 1996-10-25 | 1998-05-19 | University Of Kentucky | N-chloro-N-methyl glucamine and N-chloro-N-methyl glucamine esters as novel safe agents for water disinfection |
| EP1730163A4 (en) * | 2004-03-17 | 2009-12-30 | Panacos Pharmaceuticals Inc | Pharmaceutical salts of 3-O- (3,3-dimethylsuccinyl) betulinic acid |
| US11571431B2 (en) * | 2013-12-04 | 2023-02-07 | Galmed Research And Development Ltd | Aramchol salts |
| WO2019204298A1 (en) * | 2018-04-17 | 2019-10-24 | Cardurion Pharmaceuticals, Llc | Meglumine salts of thienopyrimidines |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4054656A (en) * | 1975-09-10 | 1977-10-18 | Mead Johnson & Company | Thieno[2,3-d]pyrimidine antiallergic agents |
-
1981
- 1981-08-21 US US06/294,962 patent/US4377583A/en not_active Expired - Fee Related
-
1982
- 1982-08-12 GR GR69028A patent/GR76250B/el unknown
- 1982-08-18 JP JP57142228A patent/JPS5843976A/ja active Granted
- 1982-08-18 ZA ZA826019A patent/ZA826019B/xx unknown
- 1982-08-19 DK DK372282A patent/DK164059C/da not_active IP Right Cessation
- 1982-08-19 PT PT75446A patent/PT75446A/pt not_active IP Right Cessation
- 1982-08-19 AU AU87430/82A patent/AU558004B2/en not_active Ceased
- 1982-08-19 CA CA000409740A patent/CA1224465A/en not_active Expired
- 1982-08-19 IT IT49006/82A patent/IT1149064B/it active
- 1982-08-20 KR KR8203744A patent/KR870001240B1/ko not_active IP Right Cessation
- 1982-08-20 BE BE0/208853A patent/BE894162A/fr not_active IP Right Cessation
- 1982-08-20 DE DE19823231103 patent/DE3231103A1/de active Granted
- 1982-08-20 GB GB08224025A patent/GB2104521B/en not_active Expired
- 1982-08-20 FI FI822907A patent/FI74965C/fi not_active IP Right Cessation
- 1982-08-20 SE SE8204792A patent/SE453504B/sv not_active IP Right Cessation
- 1982-08-20 IE IE2017/82A patent/IE53804B1/en not_active IP Right Cessation
- 1982-08-20 ES ES515156A patent/ES8401074A1/es not_active Expired
- 1982-08-20 NL NL8203280A patent/NL8203280A/nl not_active Application Discontinuation
- 1982-08-20 LU LU84346A patent/LU84346A1/fr unknown
- 1982-08-20 FR FR8214406A patent/FR2511680B1/fr not_active Expired
- 1982-08-23 AT AT0318382A patent/AT381314B/de not_active IP Right Cessation
- 1982-08-23 CH CH5001/82A patent/CH651569A5/de not_active IP Right Cessation
-
1988
- 1988-12-30 MY MY122/88A patent/MY8800122A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL268455A1 (en) | The method of manufacture of new derivatives of benzimidazole | |
| JPH05246992A (ja) | １−ヒドロキシピリド−２−オン、又はその塩から成る、患者の体内にある毒性レベルの金属を減少させるのに有効な医薬組成物 | |
| IL28200A (en) | S-triazine compounds and their production | |
| WO2004081006A1 (en) | Weak base salts | |
| SU1739845A3 (ru) | Способ получени производных изоиндолинона или их солей | |
| SE453504B (sv) | N-metyl-d-glukaminsalt av 3,4-dihydro-5-metyl-6-(2-metylpropyl)-4-oxotieno(2,3-d)-pyrimidin-2-karboxylsyra och farmaceutisk komposition innehallande detta salt | |
| AU599034B2 (en) | Furosemide salts | |
| ATE19627T1 (de) | Substituierte pyrimidin-2-one, ihre salze, verfahren zu deren herstellung und diese enthaltende zusammensetzungen. | |
| EP0028336B1 (en) | Derivative of creatinol-o-phosphate having therapeutical action, process for the preparation thereof and related pharmaceutical compositions | |
| ES8403125A1 (es) | Procedimiento para la preparacion de nuevas piridobenzodiazepinonas. | |
| US5231095A (en) | S-timolol hemihydrate | |
| JPS5726692A (en) | Preparation of stable crystal of salt of ceftizoxime | |
| JPS61180771A (ja) | 安定な抗バクテリア剤水溶液 | |
| ES8201140A1 (es) | Procedimiento para la preparacion de 2-fenilamino-imidazoli nas-(2)sustituidas. | |
| JPS595575B2 (ja) | ヒドロキシルアミンの安定化剤 | |
| SI9620056A (sl) | Postopek priprave oblike 1 ranitidin hidroklorida | |
| KR20110122202A (ko) | 플루오로퀴놀론 카르복실산 분자 결정 | |
| US3592902A (en) | Injection | |
| AU612414B2 (en) | Cephalosporin derivatives with improved pharmacokinetics, process for their preparation, pharmaceutical compositions in which they are present and synthesis intermediate | |
| PT88856B (pt) | Processo para a preparacao de 2-isoxazolinas e isoxazois fosforados e de composicoes farmaceuticas que os contem | |
| US3760086A (en) | Tranquilizer | |
| KR820001615B1 (ko) | N-펜에틸 아세트아미드 화합물의 제조방법 | |
| RU2091382C1 (ru) | Производные 4-ацетил-имидазо(4,5-в)индол-2-тиона, обладающие противогипоксической активностью и вирусингибирующей активностью в отношении вируса венесуэльского энцефаломиелита лошадей и способ их получения | |
| US2085064A (en) | Aromatic mercury cyclic alkaloid compounds and method of making them | |
| CN103288664A (zh) | 一种新的bapta衍生物、其制备方法及其医药用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAL | Patent in force |
Ref document number: 8204792-9 Format of ref document f/p: F |
|
| NUG | Patent has lapsed |
Ref document number: 8204792-9 Format of ref document f/p: F |